Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Rolski, J. [1 ]
Grodzki, T. [2 ]
Schneider, C. P. [3 ]
Zatloukal, P. [4 ]
Reck, M. [5 ]
Aitin, E. [6 ]
Tan, E. H.
机构：
[1] Maria Sklodowska Curie Mem Inst Oncol, Krakow, Poland
[2] Reg Hosp Lung Dis, Szczecin, Poland
[3] Cent Clin Bad Berka, Bad Berka, Germany
[4] Pneumol Clin, Prague, Czech Republic
[5] Krankenhaus Grosshansdorf, Grosshansdorf, Germany
[6] Hosp Carlo Poma, Mantova, Italy
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71329-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6501
引用
收藏
页码：356 / 356
页数：1
相关论文
共 50 条
  • [31] Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
    Andrea Camerini
    Cheti Puccetti
    Sara Donati
    Chiara Valsuani
    Maria Cristina Petrella
    Gianna Tartarelli
    Paolo Puccinelli
    Domenico Amoroso
    BMC Cancer, 15
  • [32] Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
    Camerini, Andrea
    Puccetti, Cheti
    Donati, Sara
    Valsuani, Chiara
    Petrella, Maria Cristina
    Tartarelli, Gianna
    Puccinelli, Paolo
    Amoroso, Domenico
    BMC CANCER, 2015, 15
  • [33] Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial
    Georgoulias, V
    Samonis, G
    Papadakis, E
    Alexopoulos, A
    Tsiafaki, X
    Rapti, A
    Veslemes, M
    Grigoratou, T
    Palamidas, P
    Kourossis, C
    Mavroudis, D
    Kakolyris, S
    Giannakakis, T
    Vlachonikolis, J
    LUNG CANCER, 2001, 34 : S47 - S51
  • [34] Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small-cell lung cancer (NSCLC): prospective analysis to improve the patient's convenience on day 8 NVBO administration
    Domine, Manuel
    Sanchez, Alfredo
    Artal, Angel
    Constenla, Manuel
    Garcia-Gomez, Ramon
    De Castro, Javier
    Vinolas, Nuria
    Sanchez-Torres, Jose M.
    Perez, Francisco J.
    Gayo, Javier
    Provencio, Mariano
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S677 - S677
  • [35] Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine with cisplatin in advanced non small cell lung cancer: End results of a phase III trial
    Gebbia, V
    Galetta, D
    Caruso, M
    LUNG CANCER, 2005, 49 : S32 - S33
  • [36] Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC); A West Japan Thoracic Oncology Group (WJTOG) study.
    Yamamoto, N
    Fukuoka, M
    Nakagawa, K
    Negoro, S
    Matui, K
    Kawahara, M
    Takada, Y
    Senba, H
    Kudo, S
    Ariyoshi, Y
    ANNALS OF ONCOLOGY, 2000, 11 : 107 - 107
  • [37] Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial.
    Pectasides, D
    Farmakis, D
    Pectasides, M
    Kostopoulou, V
    Nikolaou, M
    Koumpou, M
    Gaglia, A
    Kountourakis, P
    Mylonakis, N
    Economopoulos, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [38] Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial
    Georgoulias, V
    Ardavanis, A
    Agelidou, A
    Agelidou, M
    Chandrinos, V
    Tsaroucha, E
    Toumbis, M
    Kouroussis, C
    Syrigos, K
    Polyzos, A
    Samaras, N
    Papakotoulas, P
    Christofilakis, C
    Ziras, N
    Alegakis, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2602 - 2609
  • [39] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Results of a randomised phase II trial
    Binder, D
    Schweisfurth, H
    Grah, C
    Schäper, C
    Temmesfeld-Wollbrück, B
    Siebert, G
    Suttorp, N
    Beinert, T
    LUNG CANCER, 2005, 49 : S237 - S237
12345